In addition, when compared with GnRH agonists in women, it was demonstrated to be non-inferior and less likely to induce amenorrhea-related symptoms, while having a faster effect in controlling abnormal uterine bleedings considering that up to 50% of patients treated with daily 5 mg UPA experience amenorrhea after only 10 days of treatment [50,51]. Here, GNRH1 is linked to amenorrhea.